Where Biohaven Pharma Hldgs Stands With Analysts
Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the following analyst ratings:
Cantor Fitzgerald Maintains Overweight on Biohaven Pharma Hldgs, Raises Price Target to $165
Cantor Fitzgerald analyst Charles Duncan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Overweight and raises the price target from $151 to $165.
Cramer Gives His Opinion On Service Corporation, Vertex And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he isn't happy with the way Inseego Corp (NASDAQ: INSG) acts.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 1)
Cramer Gives His Opinion On Zillow, SoFi And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said this is a decent level at which to buy Zillow Group Inc Class A (NASDAQ: ZG) with mortgage rates so low.
What 12 Analyst Ratings Have To Say About Biohaven Pharma Hldgs
Biohaven Pharma Hldgs (NYSE:BHVN) has observed the following analyst ratings within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
UBS Downgrades Biohaven Pharma Hldgs to Neutral, Raises Price Target to $109
UBS analyst Esther Rajavelu downgrades Biohaven Pharma Hldgs (NYSE:BHVN) from Buy to Neutral and raises the price target from $108 to $109.
Biohaven Pharma: Q2 Earnings Insights
Shares of Biohaven Pharma Hldgs (NYSE:BHVN) rose 0.8% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 2.75% year over year to ($2.62), which beat the estimate of ($2.74).